Anxu Biology: It is planned to use the super-raised funds to invest in the R&D and production projects of in vitro diagnostic reagents and diagnostic instruments_ Securities Times Network

Securities Times e company news, Anxu Bio (688075) announced on the evening of January 11 that with the outbreak of the new crown epidemic, the demand for real-time detection reagents and testing instruments in various countries around the world has greatly increased, especially in foreign markets. The company plans to invest in the construction of in vitro diagnostic reagents and diagnostic instrument R&D and production projects, which will be implemented by a wholly-owned subsidiary, Xumin Biology, with an estimated total investment of 508 million yuan. The company has raised a total of 597 million yuan, and plans to use part of the raised funds to invest in the project. After the project is completed, it will further expand the company’s production scale and improve the automation level of the production line.